# Protalix BioTherapeutics

Type: Company (PLX)

Source: GetYourBrief — https://getyourbrief.com/entity/protalix-biotherapeutics
Canonical HTML page: https://getyourbrief.com/entity/protalix-biotherapeutics

## Recent coverage (4 stories, network-wide)

### General Mills and Protalix Miss Estimates as Market Eyes FY26 Guidance
2026-03-18 11:13:44 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

General Mills and Protalix BioTherapeutics both reported disappointing quarterly results on Wednesday, missing analyst expectations on both revenue and earnings. Despite the immediate misses, both companies signaled long-term stability by reaffirming or providing full-year 2026 outlooks.
Full story: https://getfinancebrief.com/story/general-mills-protalix-earnings-miss-fy26-outlook

### Protalix BioTherapeutics Misses Q4 Estimates, Sets Conservative FY26 Outlook
2026-03-18 11:13:37 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protalix BioTherapeutics reported a dual miss on revenue and earnings for the latest quarter, reflecting ongoing challenges in the commercial ramp-up of its Fabry disease treatment. Despite the shortfall, the company provided a new fiscal year 2026 outlook as it continues to leverage its plant-based protein expression platform.
Full story: https://getbiobrief.com/story/protalix-biotherapeutics-earnings-miss-fy26-outlook

### General Mills Misses Earnings Targets Amid Shifting Consumer Demand
2026-03-18 11:13:04 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2

General Mills reported disappointing results for the recent quarter, missing both revenue and earnings estimates as the consumer packaged goods sector faces persistent volume pressure. Despite the shortfall, the company reaffirmed its fiscal 2026 guidance, signaling confidence in a recovery driven by brand investment and supply chain efficiencies.
Full story: https://getretailbrief.com/story/general-mills-earnings-miss-fy26-outlook

### Protalix BioTherapeutics Misses FY26 Estimates Amid Biotech Market Volatility
2026-03-18 11:11:27 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Protalix BioTherapeutics reported misses on both top-line and bottom-line estimates for the fiscal year 2026, reflecting ongoing challenges in the rare disease therapeutic market. Despite the shortfall, the company provided a forward-looking outlook for FY26, signaling a focus on long-term clinical development and commercialization of its plant-based protein expression platform.
Full story: https://gethealthbrief.com/story/protalix-biotherapeutics-fy26-earnings-miss

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.